| Primary |
| Factor Viii Deficiency |
51.1% |
| Haemophilia |
15.1% |
| Prophylaxis |
10.2% |
| Pain |
4.9% |
| Hypertension |
2.7% |
| Psoriasis |
2.7% |
| Hemophilia A |
2.2% |
| Hiv Infection |
1.8% |
| Arthralgia |
1.3% |
| Epilepsy |
1.3% |
| Haemorrhage |
1.3% |
| Medical Diet |
1.3% |
| Arthritis |
0.9% |
| Asthma |
0.4% |
| Bacterial Infection |
0.4% |
| Bleeding |
0.4% |
| Dependence |
0.4% |
| Ear Infection |
0.4% |
| Ear Pain |
0.4% |
| Factor Viii Inhibition |
0.4% |
|
| Factor Viii Inhibition |
27.6% |
| Haemorrhage |
14.9% |
| Drug Ineffective |
6.0% |
| Off Label Use |
6.0% |
| Headache |
5.2% |
| Joint Injury |
4.5% |
| Urticaria |
4.5% |
| Arthropathy |
3.7% |
| Death |
3.7% |
| Pruritus |
3.7% |
| Haemarthrosis |
3.0% |
| Somnolence |
3.0% |
| Muscle Haemorrhage |
2.2% |
| Pneumonia |
2.2% |
| Rash |
2.2% |
| Convulsion |
1.5% |
| Hiv Infection |
1.5% |
| Mesenteric Vein Thrombosis |
1.5% |
| No Adverse Event |
1.5% |
| Product Packaging Quantity Issue |
1.5% |
|
| Secondary |
| Factor Viii Deficiency |
30.4% |
| Haemophilia |
24.8% |
| Prophylaxis |
22.4% |
| Arthralgia |
10.8% |
| Pain |
4.8% |
| Hiv Infection |
1.6% |
| Haemorrhage |
1.2% |
| Medical Diet |
1.2% |
| Arthritis |
0.8% |
| Factor Viii Inhibition |
0.8% |
| Dependence |
0.4% |
| Osteoporosis |
0.4% |
| Sleep Disorder |
0.4% |
|
| Factor Viii Inhibition |
52.4% |
| Drug Ineffective |
17.5% |
| Mesenteric Vein Thrombosis |
3.9% |
| Urticaria |
3.9% |
| Joint Injury |
2.9% |
| Convulsion |
1.9% |
| Off Label Use |
1.9% |
| Pyrexia |
1.9% |
| Somnolence |
1.9% |
| Viral Infection |
1.9% |
| Condition Aggravated |
1.0% |
| Dysgraphia |
1.0% |
| Gait Disturbance |
1.0% |
| Haemorrhage |
1.0% |
| Incorrect Route Of Drug Administration |
1.0% |
| Mouth Haemorrhage |
1.0% |
| No Adverse Event |
1.0% |
| Oedema Peripheral |
1.0% |
| Pallor |
1.0% |
| Paraesthesia |
1.0% |
|
| Concomitant |
| Pain |
66.7% |
| Factor Viii Deficiency |
33.3% |
|
|
| Interacting |
| Factor Viii Deficiency |
50.0% |
| Hypertension |
25.0% |
| Psoriasis |
25.0% |
|
| Rash |
50.0% |
| Dyspnoea |
25.0% |
| Vision Blurred |
25.0% |
|
